Showing posts with label University of Nottingham. Show all posts
Showing posts with label University of Nottingham. Show all posts

Tuesday, August 28, 2018

Gene therapy: Second stage of research documents further success for rehabilitation of tendon injuries in lame horses

Equine surgeon Milomir Kovac performs an ultrasound on a horse; ultrasound was used to monitor healing in tendon injuries in a group of race and sport horses treated with an experimental gene therapy designed to both speed healing and improve the quality of the healed injury site to prevent recurrence. (Image courtesy of University of Nottingham)

In October 2017, The Hoof Blog reported on experimental research looking into direct-injection gene therapy for soft tissue lameness injuries in horses. The authors of the 2017 paper had successfully cured lameness in two horses and published their results in the journal Frontiers in Veterinary Science.

Monday, February 19, 2018

Racing Research: Can ultrasound predict whether an injured Thoroughbred will return to racing?

Arrogate during training at 2017 Dubai World Cup


"Will he race again, Doc?" That's the question you hear trainers ask their veterinarians when a racehorse is sidelined with a tendon injury.

Veterinarians don't carry crystal balls in their trucks. Advances in equine imaging have made it possible to be much more accurate in diagnosing the severity of an injury, but it's often a matter of wait-and-see.

But now, a new tendon injury scoring system utilizes diagnostic ultrasound technology to predict a racehorse’s likelihood to return to racing. It was developed by veterinarians at Great Britain's University of Nottingham and Oakham Veterinary Hospital in Leicestershire, England in conjunction with the Hong Kong Jockey Club in China.

Friday, November 24, 2017

Clearing Dolly: Radiographs of taxidermied sheep clone's remains investigate osteoarthritis, aging


We were warned. Almost 20 years ago, skeptics and opponents of the cloning of horses and other livestock forecast musculoskeletal calamities and weaknesses. It seemed like the prophecies of doom had come true back in 2003, when reports circulated that Dolly, the famous (and first) ewe cloned  in 1996, suffered from what might be considered premature aging, in the form of osteoarthritis (OA).

Now, researchers in the United Kingdom are about to clear Dolly's name and show additional evidence of normal aging in the tribe of university-cloned sheep that followed her.

Background
Reports in 2003 that Dolly, the first animal cloned from adult cells, was suffering from osteoarthritis at the age of 5½ led to considerable scientific concern and media debate over the possibility of early-onset age-related diseases in cloned animals.

Dolly, the world's first cloned mammal from an adult cell, is on display at the National Museums of Scotland in Edinburgh. (Creative Commons file image via Wikimedia)

However, the only formal record of OA in the original Dolly was a brief mention in a conference abstract; it reported that Dolly had OA of the left knee. In the absence of the original records two research teams decided to find out for themselves whether the concerns were justified.

Researchers to the rescue

Teams at the University of Nottingham in England and the University of Glasgow in Scotland published research last year showing that a group of eight-year-old Nottingham ‘Dollies’ had aged normally. Last week, they published further evidence, in the form of a radiographic assessment of the skeletons of Dolly herself, Bonnie (her naturally conceived daughter) and Megan and Morag (the first two animals to be cloned from differentiated cells).

Their article, Radiographic assessment of the skeletons of Dolly and other clones finds no abnormal osteoarthritis, has been published in the online Nature Research Open Access journal Scientific Reports. They show that the skeletons, stored in the collections of National Museums of Scotland in Edinburgh, display radiographic OA similar to that observed in naturally-conceived sheep and Nottingham’s healthy aged clones.

Kevin Sinclair, Professor of Developmental Biology, in the School of Biosciences at the University of Nottingham, said: “No formal, comprehensive assessment of osteoarthritis in Dolly was ever undertaken. We therefore felt it necessary to set the record straight.”

Nottingham’s Dolly legacy

The four Nottingham ‘Dollies’ - Debbie, Denise, Dianna and Daisy – were derived from the cell line that gave rise to Dolly. The researchers concluded that the Nottingham Dollies had aged normally with no clinical signs of OA. They had radiographic evidence of only mild or, in one case, moderate OA.

Their results, published July last year in the academic journal Nature Communications, were in apparent stark contrast to Dolly the Sheep’s diagnosis of early onset OA which led to scientific concern and media debate over the possibility of early-onset, age-related diseases in cloned animals.

Radiographic examinations

The researchers travelled to Edinburgh and, with special permission from Dr Andrew Kitchener, Principal Curator of Vertebrates at National Museums Scotland, undertook radiographic examinations of the skeletons of Dolly and her contemporary clones.

Professor Corr said: “We found that the prevalence and distribution of radiographic-OA was similar to that observed in naturally-conceived sheep, and our healthy aged cloned sheep. As a result we conclude that the original concerns that cloning had caused early-onset OA in Dolly were unfounded.”

More about sheep and ageing
Commercially-produced sheep are rarely kept beyond the age of 6-7 years. Their natural life expectancy rarely extends beyond 9-10 years. 

The Nottingham Dollies, who would now be over 10 years of age, have been humanely euthanized but their legacy continues. Professor Sinclair and his team are currently undertaking detailed molecular studies to gain a greater insight into the aging process.

Read the Open Access article:

S. A. Corr, D. S. Gardner, S. Langley-Hobbs, M. G. Ness, A. C. Kitchener, K. D. Sinclair. Radiographic assessment of the skeletons of Dolly and other clones finds no abnormal osteoarthritis. Scientific Reports, 2017; 7 (1) DOI: 10.1038/s41598-017-15902-8

Materials kindly provided by the University of Nottingham were utilized in the creation of this article.

Background on Dolly: https://www.ed.ac.uk/news/2016/dolly-celebrates-20-years

© Fran Jurga and Hoofcare Publishing; Fran Jurga's Hoof Blog is the news service for Hoofcare and Lameness Publishing. Please, no re-use of text or images on other sites or social media without permission--please link instead. (Please ask if you need help.) The Hoof Blog may be read online at the blog page, checked via RSS feed, or received via a headlines-link email (requires signup in box at top right of blog page). Use the little envelope symbol below to email this article to others. The "translator" tool in the right sidebar will convert this article (roughly) to the language of your choice. To share this article on Facebook and other social media, click on the small symbols below the labels. Be sure to "like" the Hoofcare and Lameness Facebook page and click on "get notifications" under the page's "like" button to keep up with the hoof news on Facebook. 


Follow Hoofcare + Lameness on Twitter: @HoofBlog
Read this blog's headlines on the Hoofcare + Lameness Facebook Page
 
Disclosure of Material Connection: The Hoof Blog (Hoofcare Publishing) has not received any direct compensation for writing this post. Hoofcare Publishing has no material connection to the brands, products, or services mentioned, other than products and services of Hoofcare Publishing. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: Guides Concerning the Use of Endorsements and Testimonials in Advertising.

Wednesday, October 18, 2017

Research: Direct-Injection Gene Therapy Proven Successful for Soft Tissue Lameness Injuries in Horses

Two dressage horses recovered from suspensory ligament and superficial flexor tendon injuries following direct injection of enhanced equine DNA into the injury site. The research was published this week. (Photo: Catrin Rutland, Assistant Professor of Anatomy and Developmental Genetics, University of Nottingham School of Veterinary Medicine)


Can we use gene therapy to repair injuries? Specifically: Can genetic material (DNA) be injected directly into a soft tissue injury site and repair damaged tissue that is causing a performance or race horse to be lame?

An international group of British and Russian researchers believes that not only can it be done--they’ve done it. Twice. In a ground-breaking pair of case studies, Professor Albert Rizvanov (Kazan Federal University, Russia) and his group confirm that by injecting pure DNA into an injured horses' suspensory ligaments and superficial digital flexor tendons, they were able to completely restore the function in these vital areas.

The authors also stated that the horses presented at the clinic with naturally occurring injuries; the genetic treatment conformed with US Food and Drug Administration and EU standards. Similar treatments had been used experimentally in dogs and humans in tests by some of the team members.

The first case study was conducted on a successful 13-year-old dressage horse. The horse's clinical diagnosis was Grade 2 desmitis of the lateral branch of the suspensory ligament. A second treatment benefited a 9-year-old half-bred Trakehner, also used for dressage; he had been diagnosed with Grade 3 tendinitis of the superficial digital flexor tendon.


"We showed that gene therapy used within a period of 2–3 months after the injury resulted in the complete recovery of functions and full restoration of the severely damaged suspensory ligament and superficial digital flexor tendon," the authors state in the article.

The research also showed that the tissue within the limbs had fully recovered and that 12 months after the revolutionary treatment, the horses were completely fit, active and pain free.

No side effects or adverse reactions were seen in the horses.

The main advantage of gene therapy used in this study was the application of a combination of the pro-angiogenic growth factor gene VEGF164, enhancing growth of blood vessels, and bone morphogenetic protein 2 (BMP2), which plays an important role in the development of bone and cartilage.

To avoid undesirable immune reactions, both genes were derived from horses, thus resulting in biosynthesis of natural horse proteins in treated animals. Both recombinant genes were cloned into single plasmid DNA which is commonly regarded as non-immunogenic and a biologically safe gene therapy vector.

Since these injuries may affect not only horses but many other animals and humans, the study carries potential implications for the future direction of human and veterinary medicine, potentially with fewer relapses and shorter recovery times. Much more work will be needed to investigate safety and efficacy. A larger clinical trial has been started.

Professor Rizvanov formed a collaboration with scientists and clinicians within his laboratories at Kazan Federal University, Kazan, Russia and also with Moscow State Academy of Veterinary Medicine and Biotechnology, Russia and the School of Veterinary Medicine and Science, University of Nottingham, United Kingdom. Working together to heal ligament and tendon injuries has been the primary goal of the work.

Their work has now been published in the international journal Frontiers in Veterinary Science and is titled “Gene Therapy Using Plasmid DNA Encoding Vascular Endothelial Growth Factor 164 and Fibroblast Growth Factor 2 Genes for the Treatment of Horse Tendinitis and Desmitis: Case Reports.”

To read the full article please go to: https://www.frontiersin.org/articles/10.3389/fvets.2017.00168/full

Full citation:
Kovac Milomir, Litvin Yaroslav A., Aliev Ruslan O., Zakirova Elena Yu, Rutland Catrin S., Kiyasov Andrey P., Rizvanov Albert A. (2017) Gene Therapy Using Plasmid DNA Encoding Vascular Endothelial Growth Factor 164 and Fibroblast Growth Factor 2 Genes for the Treatment of Horse Tendinitis and Desmitis: Case Reports. Frontiers in Veterinary Science. 4. DOI=10.3389/fvets.2017.00168.

For more information, contact Professor Albert Rizvanov: albert.rizvanov@kpfu.ru.

Dr. Rutland's imaging work was displayed on the cover of the September 2017 edition of HoofSearch. She assisted with the preparation of this article.


© Fran Jurga and Hoofcare Publishing; Fran Jurga's Hoof Blog is the news service for Hoofcare and Lameness Publishing. Please, no re-use of text or images on other sites or social media without permission--please link instead. (Please ask if you need help.) The Hoof Blog may be read online at the blog page, checked via RSS feed, or received via a headlines-link email (requires signup in box at top right of blog page). Use the little envelope symbol below to email this article to others. The "translator" tool in the right sidebar will convert this article (roughly) to the language of your choice. To share this article on Facebook and other social media, click on the small symbols below the labels. Be sure to "like" the Hoofcare and Lameness Facebook page and click on "get notifications" under the page's "like" button to keep up with the hoof news on Facebook. 
Follow Hoofcare + Lameness on Twitter: @HoofBlog
Read this blog's headlines on the Hoofcare + Lameness Facebook Page
 
Disclosure of Material Connection: The Hoof Blog (Hoofcare Publishing) has not received any direct compensation for writing this post. Hoofcare Publishing has no material connection to the brands, products, or services mentioned, other than products and services of Hoofcare Publishing. I am disclosing this in accordance with the Federal Trade Commission’s 16 CFR, Part 255: Guides Concerning the Use of Endorsements and Testimonials in Advertising.